NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $348 | $19,145 | $2,978 | $12,772 |
| % Growth | -98.2% | 542.9% | -76.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $348 | $19,145 | $2,978 | $12,772 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $30,971 | $27,516 | $44,751 | $34,895 |
| G&A Expenses | $24,520 | $27,264 | $27,152 | $35,454 |
| SG&A Expenses | $24,520 | $27,264 | $27,152 | $24,311 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$11,143 |
| Other Operating Expenses | $0 | $0 | $0 | -$3,205 |
| Operating Expenses | $55,491 | $54,780 | $71,903 | $56,001 |
| Operating Income | -$55,143 | -$35,635 | -$68,925 | -$43,229 |
| % Margin | -15,845.7% | -186.1% | -2,314.5% | -338.5% |
| Other Income/Exp. Net | -$16,862 | $18,271 | $29,398 | -$48,948 |
| Pre-Tax Income | -$72,005 | -$17,364 | -$39,527 | -$92,177 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$72,005 | -$17,364 | -$39,527 | -$92,177 |
| % Margin | -20,691.1% | -90.7% | -1,327.3% | -721.7% |
| EPS | -0.61 | -0.15 | -0.34 | -0.98 |
| % Growth | -306.7% | 55.9% | 65.3% | – |
| EPS Diluted | -0.61 | -0.15 | -0.34 | -0.98 |
| Weighted Avg Shares Out | 119,000 | 112,510 | 116,125 | 97,028 |
| Weighted Avg Shares Out Dil | 119,000 | 112,510 | 116,125 | 97,028 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,713 | $7,055 | $7,351 | $4,485 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $64 | $45 | $52 | $51 |
| EBITDA | -$71,941 | -$35,590 | -$68,873 | -$111,693 |
| % Margin | -20,672.7% | -185.9% | -2,312.7% | -874.5% |